<DOC>
	<DOCNO>NCT00813358</DOCNO>
	<brief_summary>The Zenith TX2® Post-market Approval Study clinical trial approve US FDA study safety effectiveness Zenith TX2® TAA Endovascular Graft treatment thoracic aortic aneurysm .</brief_summary>
	<brief_title>Zenith TX2® Post-market Approval Study</brief_title>
	<detailed_description />
	<mesh_term>Aneurysm</mesh_term>
	<mesh_term>Aortic Aneurysm</mesh_term>
	<mesh_term>Aortic Aneurysm , Thoracic</mesh_term>
	<criteria>Descending thoracic aortic aneurysm diameter great equal 5.0 cm ; Descending thoracic aortic aneurysm history growth great equal 0.5 cm within previous 12 month ; Descending thoracic aortic degenerative atherosclerotic ulcer great equal 10 mm depth 20 mm diameter Age le 18 year Other medical condition may cause patient noncompliant protocol , confound result , associate limited life expectancy ( i.e. , less 2 year ) Pregnant , breastfeeding , plan become pregnant within 24 month Unwilling unable comply followup schedule Inability refusal give inform consent Simultaneously participate another investigative device drug study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Endovascular Aneurysm Repair</keyword>
	<keyword>Aortic Aneurysm</keyword>
	<keyword>Thoracic</keyword>
</DOC>